Moderna has announced that a COVID-19 vaccine it is developing has shown promise.<br />The U.S. biotech company says its vaccine has induced a "rapid and strong" immune response against the virus.<br />According to UPI, late-stage testing will begin in less than two weeks.<br />In initial trials, healthy adult volunteers under 55 years-old were given two doses of the vaccine separated by 28 days.<br />All participants who received doses of the drug reported only mild reactions such as fatigue, chills, and headaches.<br />The company said it will start the third study phase of the vaccine candidate on July 23 with 30,000 participants.
